Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlpN GBS monoclonal antibodies
- Development stage
- Preclinical
- Lead developer
- Minervax
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AlpN GBS monoclonal antibodies are a series of therapeutic antibodies being developed by Minervax to target the Alpha-like protein family (AlpN) of Group B Streptococcus (GBS). These antibodies are designed to recognize and bind to highly conserved N-terminal domains of AlpN antigens, including AlpC, Rib, Alp1, and Alp2/3, which are also the components of Minervax's lead vaccine candidate. By binding to these surface proteins, the monoclonal antibodies aim to neutralize the bacteria and promote their clearance by the immune system. This approach is intended to prevent or treat invasive GBS infections, particularly in newborns and vulnerable adults, serving as either an alternative or a complement to maternal vaccination strategies. The program is currently in early preclinical development.
- Other names
- AlpN monoclonal antibodiesGBS monoclonal antibodiesAlpN GBS Monoclonal Antibodies
02
Targets
Group B Streptococcus alpha-like protein N-terminal domain
Beyond the preview
Go deeper on AlpN GBS monoclonal antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlpN GBS monoclonal antibodies.